Post

USC Schaeffer
@schaeffer.usc.edu

FDA reviewers can't possibly keep pace with software development in the age of machine learning and AI, USC Schaeffer's Dana Goldman writes in @statnews.com Congress must give FDA the tools it needs to adapt so patients can access -- and have confidence in -- the latest innovations, he argues.

statnews.comI’m using not-FDA-approved software to manage my diabetes. I’ve never felt better“It is no longer possible to ask the FDA to keep pace with software development by doing the same reviews faster,” writes Dana Goldman.

0 reposts1 like

No replies yet.